The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Bruker (NASDAQ: BRKR) and the rest of the research tools & consumables stocks fared in Q4.

The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives.

The 10 research tools & consumables stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 1.2% while next quarter’s revenue guidance was in line.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 11.7% since the latest earnings results.

Bruker (NASDAQ: BRKR)

With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ: BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.

Bruker reported revenues of $977.2 million, flat year on year. This print exceeded analysts’ expectations by 1.4%. Overall, it was a satisfactory quarter for the company with full-year revenue guidance exceeding analysts’ expectations but a significant miss of analysts’ EPS estimates.

Unsurprisingly, the stock is down 7.8% since reporting and currently trades at $39.12.

Is now the time to buy Bruker? Access our full analysis of the earnings results here, it’s free.

Best Q4: Bio-Techne (NASDAQ: TECH)

With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ: TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.

Bio-Techne reported revenues of $295.9 million, flat year on year, outperforming analysts’ expectations by 2%. The business had a strong quarter with an impressive beat of analysts’ organic revenue estimates and a decent beat of analysts’ revenue estimates.

Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 10.4% since reporting. It currently trades at $57.88.

Is now the time to buy Bio-Techne? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: Mettler-Toledo (NYSE: MTD)

With roots dating back to the precision balance innovations of Swiss engineer Erhard Mettler, Mettler-Toledo (NYSE: MTD) manufactures precision weighing instruments, analytical equipment, and product inspection systems used in laboratories, industrial settings, and food retail.

Mettler-Toledo reported revenues of $1.13 billion, up 8.1% year on year, exceeding analysts’ expectations by 2.3%. Still, it was a slower quarter as it posted revenue guidance for next quarter missing analysts’ expectations significantly and a significant miss of analysts’ EPS guidance for next quarter estimates.

As expected, the stock is down 6.9% since the results and currently trades at $1,287.

Read our full analysis of Mettler-Toledo’s results here.

Waters Corporation (NYSE: WAT)

Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE: WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing.

Waters Corporation reported revenues of $932.4 million, down 45.4% year on year. This result met analysts’ expectations. Aside from that, it was a mixed quarter as it also produced revenue guidance for next quarter exceeding analysts’ expectations but a significant miss of analysts’ EPS guidance for next quarter estimates.

Waters Corporation had the slowest revenue growth among its peers. The stock is down 16.5% since reporting and currently trades at $318.41.

Read our full, actionable report on Waters Corporation here, it’s free.

Sotera Health Company (NASDAQ: SHC)

With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use.

Sotera Health Company reported revenues of $303.4 million, up 4.6% year on year. This number beat analysts’ expectations by 1.2%. It was a strong quarter as it also logged a solid beat of analysts’ full-year EPS guidance estimates and full-year revenue guidance slightly topping analysts’ expectations.

Sotera Health Company pulled off the highest full-year guidance raise among its peers. The stock is down 12.8% since reporting and currently trades at $15.25.

Read our full, actionable report on Sotera Health Company here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.